Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874887 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
A Phase 4 study of Anti-biotic Resistance, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT00874887: Completed Phase 4 study of Anti-biotic Resistance, sponsored by Allergan.
NCT00874887 is a Phase 4 study of Anti-biotic Resistance that has completed, run by Allergan. The registered enrollment target is 66 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00874887, a Phase 4 study of Anti-biotic Resistance, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
Primary Outcome
Percentage of subjects with strain resistance as determined by Minimum Inhibitory Concentration (MIC) of the conjunctiva (clear membrane covering the white surface of the eye) at day 14. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. The MIC cut-off values include: Intermediate is 1 to less than 2; Resistant is greater than or equal to 2.
Conditions Studied
Interventions
- DRUG moxifloxacin 0.5% HCI ophthalmic solution
- DRUG gatifloxacin ophthalmic solution 0.3%
Study Locations (2)
Minnesota
- - Minneapolis
Saskatchewan
- - Saskatoon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00874887 record still lists
NCT00874887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Anti-biotic Resistance appearing as the primary indexed condition, and to 2 interventions - of which moxifloxacin 0.5% HCI ophthalmic solution is the first listed.
NCT00874887 reports a single indexed study location in Minnesota, Saskatchewan.
Frequently Asked Questions
What is clinical trial NCT00874887 about?
NCT00874887 is a clinical study titled "A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms". The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
What is the current status of trial NCT00874887?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2009-03. Estimated completion is 2009-10.
What conditions does trial NCT00874887 study?
This clinical trial studies the following conditions: Anti-biotic Resistance.
What interventions are being tested in trial NCT00874887?
The interventions under investigation include: moxifloxacin 0.5% HCI ophthalmic solution (DRUG), gatifloxacin ophthalmic solution 0.3% (DRUG).
Who is sponsoring clinical trial NCT00874887?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874887 being conducted?
This trial has 2 study locations across Minnesota, Saskatchewan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00874887's enrollment target sits among peer trials
66 1083rd of 2000 higher than 910 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia